Neurological Institute of New York

EQS-News: Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
목요일, 6월 1, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic’s management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
화요일, 5월 30, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Vaccine, Short course immune induction therapy

NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic's management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

Children’s Hospital Los Angeles Names Ashish Buttan Vice President, Physician Partnerships

Retrieved on: 
화요일, 7월 12, 2022
Mental Health, Health, Consumer, Hospitals, Neurology, Children, CHLA, Fortis Healthcare, Blog, Faculty, Program, Multimedia, Leadership, Neurological Institute of New York, Keck School of Medicine of USC, Medicine, YouTube, LinkedIn, Transformation, No, Partnership, Department of Psychology, University of Oslo, Patient, Instagram, Financial management, MBA, Physician, Development of the human body, USC, Strategic planning, Children's Hospital Los Angeles, National Institutes of Health, Division, Hospital, U.S. News & World Report, Department, Research, News, Twitter, BDS, National, Management, Neuroscience, Facebook

Ashish Buttan, BDS, MBA, has been promoted to Vice President, Physician Partnerships at Childrens Hospital Los Angeles (CHLA).

Key Points: 
  • Ashish Buttan, BDS, MBA, has been promoted to Vice President, Physician Partnerships at Childrens Hospital Los Angeles (CHLA).
  • View the full release here: https://www.businesswire.com/news/home/20220712006172/en/
    As Vice President, Buttan will work with administrative and department leaders to support business and strategic planning for physician resources in hospital programs and service lines.
  • Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country and the greater Southern California region.
  • Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No.

Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621

Retrieved on: 
월요일, 11월 1, 2021
Myopathy, CDD, European Medicines Agency, Complutense University of Madrid, Natural history, Peaceful transition of power, Clinical trial, Columbia University, Albert Einstein College of Medicine, Publication, Research institute, Division, GLOBE, Degenerative disease, Research, Molecular biology, Children's Medical Research Institute, TK2, Epilepsy, KOL, Montreal Neurological Institute and Hospital, Columbia University Irving Medical Center, Pyrimidine, Lennox–Gastaut syndrome, Lucy, Continuation, Q&A, ALS, Seizure, DNA, Fenfluramine, Dravet syndrome, Neurological Institute of New York, NASDAQ, FDA, Neuromuscular medicine, Mitochondrial disease, Muscle, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.

Key Points: 
  • EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.
  • Dr. Galer will discuss the ongoing late-stage MT-1621 clinical program and remaining pathway to regulatory submissions.
  • She holds a doctorate from the Complutense University of Madrid with the thesis entitled: "Application of Personalized Medicine in Mitochondrial Pathology: treatment with pyrimidine nucleosides in thymidine kinase 2 deficiency (TK2d)".
  • The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.